nuere, thanks for your kind reply. I was looking for an explanation as to why in other "high telomerase expression" hematologic malignancies, imetelstat was not particularly effective, at least clinically, e.g. CLL and myeloma and the abstract you found might provide a partial explanation if some TERT variants are more sensitive to imetelstat than others and perhaps that's how they should be screening patients rather than looking at telomere length. If PV, ET and MF has a common germ-line gene variant than perhaps the results of the phase II ET study (quite impressive I thought, but not terribly clinically relevant unfortunately because of other well established treatments for ET) might truly extrapolate to other MPNs. Is your background genetics? You seem pretty well grounded here. Thanks for your response. Interesting the the Mayo study has been expanded to include a third cohort of patient with post MF leukemia. It would be wonderful for these patients if some effective therapy could be found. Regards, bp
